168 related articles for article (PubMed ID: 35645805)
61. Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways.
Kogai T; Ohashi E; Jacobs MS; Sajid-Crockett S; Fisher ML; Kanamoto Y; Brent GA
J Clin Endocrinol Metab; 2008 May; 93(5):1884-92. PubMed ID: 18319322
[TBL] [Abstract][Full Text] [Related]
62. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Kogai T; Taki K; Brent GA
Endocr Relat Cancer; 2006 Sep; 13(3):797-826. PubMed ID: 16954431
[TBL] [Abstract][Full Text] [Related]
63. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
[TBL] [Abstract][Full Text] [Related]
64. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
65. Radioiodine therapy of thyroid carcinoma following Pax-8 gene transfer.
Mu D; Huang R; Ma X; Li S; Kuang A
Gene Ther; 2012 Apr; 19(4):435-42. PubMed ID: 21833035
[TBL] [Abstract][Full Text] [Related]
66. KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells.
Beyer S; Lakshmanan A; Liu YY; Zhang X; Wapnir I; Smolenski A; Jhiang S
Endocrinology; 2011 Mar; 152(3):782-92. PubMed ID: 21209020
[TBL] [Abstract][Full Text] [Related]
67. Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression.
Li L; Lv B; Chen B; Guan M; Sun Y; Li H; Zhang B; Ding C; He S; Zeng Q
Biochem Biophys Res Commun; 2015 Jul; 462(4):314-21. PubMed ID: 25960292
[TBL] [Abstract][Full Text] [Related]
68. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
[TBL] [Abstract][Full Text] [Related]
69. Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study.
Lu YL; Chen ST; Ho TY; Chan WH; Wong RJ; Hsueh C; Lin SF
World J Clin Cases; 2021 Jan; 9(1):71-80. PubMed ID: 33511173
[TBL] [Abstract][Full Text] [Related]
70. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
71. Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization.
Lan L; Basourakos S; Cui D; Zuo X; Deng W; Huo L; Chen L; Zhang G; Deng L; Shi B; Luo Y
Oncol Rep; 2017 Jan; 37(1):426-434. PubMed ID: 27840971
[TBL] [Abstract][Full Text] [Related]
72. Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells.
Liu YY; Zhang X; Ringel MD; Jhiang SM
Endocr Relat Cancer; 2012 Jun; 19(3):291-304. PubMed ID: 22355179
[TBL] [Abstract][Full Text] [Related]
73. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back.
Ahn BC
Theranostics; 2012; 2(4):392-402. PubMed ID: 22539935
[TBL] [Abstract][Full Text] [Related]
74. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells.
Ohashi E; Kogai T; Kagechika H; Brent GA
Cancer Res; 2009 Apr; 69(8):3443-50. PubMed ID: 19351850
[TBL] [Abstract][Full Text] [Related]
75. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
Kogai T; Brent GA
Pharmacol Ther; 2012 Sep; 135(3):355-70. PubMed ID: 22750642
[TBL] [Abstract][Full Text] [Related]
76. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
77. Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
Massimino M; Tirrò E; Stella S; Frasca F; Vella V; Sciacca L; Pennisi MS; Vitale SR; Puma A; Romano C; Manzella L
Anticancer Res; 2018 Dec; 38(12):6653-6662. PubMed ID: 30504373
[TBL] [Abstract][Full Text] [Related]
78. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells.
Pugliese M; Fortunati N; Germano A; Asioli S; Marano F; Palestini N; Frairia R; Boccuzzi G; Catalano MG
Thyroid; 2013 Jul; 23(7):838-46. PubMed ID: 23531031
[TBL] [Abstract][Full Text] [Related]
79. Linking loss of sodium-iodide symporter expression to DNA damage.
Lyckesvärd MN; Kapoor N; Ingeson-Carlsson C; Carlsson T; Karlsson JO; Postgård P; Himmelman J; Forssell-Aronsson E; Hammarsten O; Nilsson M
Exp Cell Res; 2016 May; 344(1):120-131. PubMed ID: 27108928
[TBL] [Abstract][Full Text] [Related]
80. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Nilubol N; Merkel R; Yang L; Patel D; Reynolds JC; Sadowski SM; Neychev V; Kebebew E
Clin Endocrinol (Oxf); 2017 Jan; 86(1):128-133. PubMed ID: 27392538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
